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Background: Guaranà (Paulinia cupana) seed extracts are increasingly popular worldwide for their stimulant,
cognitive and behavioral effects. To assess the effects on psychological well-being, anxiety and mood of a
commercially available guaranà preparation taken regularly over several days according to the labelled dosages and
instructions, 27 healthy volunteers were enrolled in a prospective, randomized, single-blind, placebo-controlled,
crossover study.
Results: Guaranà 350 mg × 3 daily just after breakfast or placebo were given for 5 consecutive days. Assessment
was performed one day after the last intake and included the psychological well-being (PWB) scales, the self-rating
anxiety state scale (SAS), and the Bond–Lader mood scales. There were no significant differences between guaranà
and placebo in any of the 6 areas of PWB, in SAS, as well as in any of the 16 mood scales.
Conclusions: In healthy subjects a 5-day treatment with a commercial preparation of guaranà used according to
labelled instructions provided no evidence for any major effects on psychological well-being, anxiety and mood.
Considering the increasing popularity of guaranà-containing products sold as dietary supplements for fitness
purposes, controlled studies are strongly warranted to assess their benefits in comparison to the labelled claims.
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Guaranà (Paulinia cupana) is an Amazonian creeping
shrub which has been used for centuries by Amerindian
tribes for several indications, including: cardiovascular
drug, preventive for arteriosclerosis, pain-reliever, astrin-
gent, stimulant, tonic, to treat diarrhea, hypertension,
fever, migraine, neuralgia and dysentery [1]. Guaranà
seed extracts however over the last few decades became
increasingly popular worldwide mainly for their stimu-
lant and thermogenic actions, as ingredients in many
herbal formulas, energy drinks, and protein bars [1].
Several studies addressed the stimulant, cognitive and
behavioral effects of guaranà [2]. In particular, various
double-blind, placebo-controlled studies in human* Correspondence: marco.cosentino@uninsubria.it
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reproduction in any medium, provided the orsubjects showed that guaranà acutely improves some pa-
rameters of cognitive performance without effects on
mood [3], enhances secondary memory performance and
increases alert and some content mood ratings [4], in-
creases speed and accuracy of performing rapid visual
information processing tasks and attenuates mental fa-
tigue associated with extended task performance [5]. At
least one controlled study however failed to report any
effects on psychomotor speed and accuracy, memory,
visuomotor performance, planning and problem solving
[6]. Conflicting results have been reported also in the
few studies which addressed the effects of guaranà after
long-term administration. Indeed, in two recent
randomised, cross-over, placebo-controlled studies in
breast cancer patients, guarana was effective in reducing
fatigue during systemic chemotherapy [7] but had no ef-
fect on radiation-induced fatigue and depression [8].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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long-term administration of guaranà had no significant
effects on the cognition of normal, elderly volunteers [9].
Commercial products currently available on the mar-
ket usually contain guaraná extracts which are con-
centrated and standardized to the caffeine content.
Commonly recommended dosages correspond to 20–30
mg of caffeine per day while usually no instructions are
provided about optimal duration of use. Indeed, guaranà
is generally regarded as safe by the Food and Drug Ad-
ministration Center for Food Safety and Applied Nutri-
tion [10]. These products are usually marketed with
claims of effectiveness, but the weight of the evidence is
very small for most of them. A recent survey found that
guaranà is among the most common herbal ingredients
sold over the Internet even for use as legal alternatives
to illicit drugs of abuse [11]. Additional concern comes
from the observation that potential uses suggested in
websites include mood enhancement as well as treat-
ment of depression, together with the suggestion that
guaranà may increase feelings of well-being. To our best
knowledge however no evidence exists so far which
might support those claims, except for a report showing,
after acute administration of guaranà, increased alert rat-
ings and improved content ratings measured by use of
the Bond-Lader mood scales [4]. Guaranà contains large
amounts of caffeine, as well as trace amounts of theo-
phylline and theobromine, which are believed to contrib-
ute significantly to guaranà effects [1]. Indeed moderate
intake of caffeine has been associated with less depres-
sive symptoms, although its effects on mood never re-
ceived thorough investigation [12].
Considering the increasing popularity of guaranà-
containing products and the paucity of evidence regard-
ing their actual effectiveness, we decided to assess in
healthy subjects the effects on psychological well-being,
anxiety and mood of a commercially available guaranà




Twenty-seven volunteers (9 female and 18 male, age
(mean ± SD) 25.4 ± 6.4 years) were enrolled in a pro-
spective, randomized, single-blind, placebo-controlled,
crossover protocol evaluating the effects on psycho-
logical well-being, anxiety and mood of the intake for
five consecutive days of a guaranà extract at 360 mg × 3
daily just after breakfast, according to labelled advice All
the subjects enrolled successfully concluded the study,
regularly taking all the capsules in the two treatment pe-
riods and participating to all the 4 evaluation sessions.
No subjects reported any adverse event in any of the
evaluation sessions.Psychological well-being
There were no significant differences among evaluation
sessions in the scores of subjects taken as a whole in any
of the 6 areas of psychological well-being, and in par-
ticular there was no significant difference between the
effects of guaranà and placebo (Table 1).
When subjects were divided according to gender, no
signficant difference was observed in males (guaranà vs
placebo: autonomy, P = 0.727; environmental mastery:
P = 0.979; personal growth: P = 1.000; positive relations:
P = 0.698; purpose in life: P = 0.298; self-acceptance: P =
0.991), while in females after guaranà there was a signifi-
cant increase in the self-acceptance area (59.1 ± 9.3 with
placebo vs 63.0 ± 9.4 with guaranà, P = 0.033) but not in
any of the other areas (autonomy, P = 0.955; environ-
mental mastery: P = 0.626; personal growth: P = 0.999;
positive relations: P = 1.000; purpose in life: P = 0.329).
Subjects were also divided in two groups according
to the median score obtained for each area after placebo, to
test for any difference between lower- and higher-scoring
subjects, however no significant difference occurred be-
tween the effects of guaranà and placebo in either groups
(lower-scoring group: autonomy, P = 0.990; environmental
mastery: P = 0.769; personal growth: P = 0.934; positive rela-
tions: P = 0.989; purpose in life: P = 0.998; self-acceptance:
P = 0.412; higher-scoring group: autonomy, P = 0.339; envir-
onmental mastery: P = 0.959; personal growth: P = 0.784;
positive relations: P = 0.065; purpose in life: P = 0.453;
self-acceptance: P = 0.994).
Self-rating anxiety
The scores obtained in the evaluations sessions were:
pretreatment 33.8 ± 7.0, placebo 32.4 ± 6.9, washout
31.2 ± 6.7, guaranà 32.2 ± 7.3.
There were no significant differences among evalu-
ation sessions in the scores of subjects taken as a whole
(F = 2.410, DFd = 57.49, P = 0.093; guaranà vs placebo:
P = 0.992).
The effect of guaranà was not significantly different
from the effect of placebo even in comparisons
according to gender (female: P = 0.059; male: P = 0.895)
and to the low or high scores obtained after placebo
(low scores: P = 0.909; high scores: P = 0.797).
Mood
There was no significant effect of the treatments on
mood as assessed by the Bond–Lader mood scales
(Table 2).
The effect of guaranà and placebo did not significantly
differ even according to gender (female: alert, P = 0.362;
calm: P = 0.999; content: P = 0.971; male: alert, P = 0.998;
calm: P = 0.979; content: P = 0.901) or to the lower or
higher scores obtained after placebo (lower-scoring
group: alert, P = 0.190; calm: P = 0.533; content: P =
Table 1 Scores from the PWB scales for the six areas of psychological well-being
Areas of psychological well-being Pretreatment Placebo Washout Guaranà Two-way ANOVA (F, DFd, P) Guaranà vs Placebo (P)
Autonomy 64.5 ± 9.0 65.4 ± 10.4 64.9 ± 9.2 64.7 ± 10.9 0.267, 62.30, 0.805 0.921
Environmental mastery 60.8 ± 9.1 61.4 ± 10.1 62.6 ± 8.9 61.9 ± 10.1 1.207, 63.40, 0.311 0.965
Personal growth 66.9 ± 6.3 66.3 ± 8.1 66.0 ± 7.9 66.3 ± 7.8 0.382, 59.33, 0.711 1.000
Positive relations 64.4 ± 7.6 63.3 ± 8.4 62.7 ± 8.4 62.5 ± 7.9 1.538, 59.08, 0.221 0.781
Purpose in life 63.6 ± 9.2 64.4 ± 8.2 64.7 ± 8.8 63.6 ± 8.8 0.722, 53.84, 0.495 0.810
Self-acceptance 61.4 ± 13.1 61.7 ± 11.1 62.4 ± 10.9 62.8 ± 11.4 0.928, 57.63, 0.410 0.540
Data are means ± SD.
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0.810; content: P = 0.395).
Statistical power analysis
The least hypothetical differences between the effects of
guaranà and placebo which could be detected in the
whole study population in each test at the 0.05 signifi-
cance level and with a power value of 0.80 were as
follows:





Data a Autonomy: 2.80
 Environmental mastery: 2.43
 Personal growth: 2.10
 Positive relations: 2.32
 Purpose in life: 2.32
 Self-acceptance: 2.32– SAS scale: 2.21
– Bond–Lader VAS: Alert: 8.57
 Calm: 11.48
 Content: 11.59Discussion
The purpose of our study was to assess in a population
of healthy subjects the effects of a commercially avail-
able guaranà preparation on psychological well-being,
anxiety and mood when the product was used according
to the labelled dosages and instructions. Results provide
no evidence for any major effects of guaranà on the psy-
chological tests employed. The only significant difference
in favour of guaranà was found in female subjects and it
was limited to just one of the six areas of psychological
well-being (namely, self-acceptance), thus it cannot be
excluded that it represents just a random finding. Givene 2 Scores from the Bond–Lader VAS
factors Pretreatment Placebo Washout Gu
lert 29.9 ± 14.9 33.1 ± 18.3 28.7 ± 13.8 30.0
alm 40.0 ± 22.0 39.3 ± 23.6 39.0 ± 21.7 38.0
ntent 26.4 ± 16.4 33.7 ± 21.9 29.8 ± 17.6 30.4
re means ± SD.the null results reported, it is important to consider
whether the study was adequately powered to detect sig-
nificant effects if they existed. Power analysis of the re-
sults show that the least hypothetical differences
between the effects of guaranà and placebo which could
be detected in our study were in the range 2.1-2.8 for
PWB scales and 2.2 for the SAS scale, while they were in
the range 8.6-11.6 for the Bond–Lader scales. Least
hypothetical differences are therefore very small for the
PWB scales and for the SA scale. In particular, each of
the PWB scales may range 14–84 [13-15], thus the least
detectable differences would be just 3.5% of the entire
interval, which is highly unlikely to be somehow clinic-
ally significant. For the SAS scale total scores range from
20–80 and clinically relevant intervals are: 20–44 nor-
mal, 45–59 mild to moderate anxiety, 60–74 marked to
severe anxiety, 75–80 extreme anxiety [16]. Intervals are
therefore nearly seven-fold higher than the least detect-
able differences in the present study, thus it is unlikely
that any significant effects could have been overlooked.
As for the Bond Lader scales, least detectable differences
in our study were in the range 8.6-11.6. The Bond Lader
scales were used in at least one previous study showing
positive results with guaranà [4]: after acute administra-
tion of guaranà to 26 healthy subjects (18 females, 8
males) there were statistically significant increases of
alert and content ratings, the size being in both cases on
average around 6–7 units, a difference which could have
been overlooked in our setting. Nonetheless, according
to our results the average differences observed between
placebo and guaranà in either alert, content and calm
were in the range 1.3-3.3, therefore unlikely to be clinic-
ally relevant and in any case half or less those found in
the study by Haskell et al. [4]. It should be noted that
also Kennedy et al. [3] examined the effects of a singlearanà Two-way ANOVA (F, DFd, P) Guaranà vs Placebo (P)
± 15.1 0.948, 59.95, 0.404 0.733
± 22.1 0.099, 55.15, 0.915 0.989
± 14.8 1.671, 64.43, 0.190 0.858
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scales. They reported no signifcant effects, however they
also provided no figures and it is therefore not possible
to compare those results with the present findings.
Studies investigating the neurobehavioural effects of
guaranà in humans so far considered mainly the acute
effects. Kennedy and co-workers [3] used 75 mg of a
dried ethanolic extract of guaranà and found positive ef-
fects on some tasks of the Cognitive Drug Research
(CDR) computerised assessment and on the Serial sub-
traction task, and in particular improvements to speed
of attention, secondary memory, serial subtractions and
speed of sentence verification, but no effects on the
Bond-Lader mood scales. The same group in a subse-
quent study [5] showed that 222 mg of guaranà
(containing 40 mg caffeine) added to vitamin/mineral ef-
fervescent tablets improved task performance, in com-
parison to placebo, in terms of both increased speed and
accuracy of performing the Rapid Visual Information
Processing and attenuated mental fatigue associated with
extended task performance. Haskell and co-workers [4]
used a standardized guaranà extract containing 11-12%
caffeine and found positive effects on secondary memory
performance in the CDR computerised assessment with
37.5 and 75 mg, on alert ratings of the Bond-Lader
mood scales with 300 mg and on content ratings with
37.5, 75, 150 and 300 mg. Fernandes Galduróz and de
Araújo Carlini [6], who failed to report any effects with
guaranà, evaluated 1000 mg guaranà containing 21 mg
caffeine on tests of psychomotor speed and accuracy
(letter cancellation), working memory (digit span and
digit symbol substitution), memory (free recall and
learned material) and the Mosaic test (involving visuo-
motor performance, planning and problem solving). No
effect was also found on anxiety and quality of sleep.
Just a few studies addressed the effects of guaranà after
prolonged administration. The study by de Oliveira
Campos and co-workers [7] examined the effects of
50 mg guaranà by mouth twice daily for 21 days in 75
breast cancer patients receiving systemic chemotherapy
using a double-blinded procedure and found positive re-
sults on several fatigue scales with no worsening of sleep
quality or anxiety or depression. In another double-
blinded, cross-over study, da Costa Miranda et al. [8]
randomized 36 patients with breast cancer undergoing
adjuvant radiation therapy to either guaranà 75 mg daily
for 28 days or to placebo and found no effect on
radiation-induced fatigue and depression. Fernandes
Galduróz and de Araújo Carlini [9] administered 1 g of
powdered guaranà (containing 2.1% caffeine) per day for
five months to normal, elderly volunteers who were eval-
uated at baseline and after 3 and 5 months. Evaluations
included the Mini-Mental State as screening for demen-
tia, the Digital Span to assess immediate memory, theFree Recall for recent memory, Digital Symbol for psy-
chomotor activity and concentration, Cancellation tests
for vigilance and attention, the Mosaic test for visual
and spatial organization, the Rave-Progressive Matrices
for general abilities, and in addition quality of sleep and
anxiety were assessed. No significant effects were
detected on any of the functions tested and in addition
no subjects reported any rise in libido or improved sex-
ual performance.
Based upon available literature, it appears therefore
that guaranà has been investigated mainly as a stimulant,
in agreement with its chemical composition, while the
possible effects of guaranà on mood have been only oc-
casionally considered. So far only Haskell et al. [4]
reported some positive results on mood, while Kennedy
et al. [3] failed to observe any significant effects. None-
theless, in both cases single doses of guaranà were stud-
ied and short-term effects were reported.
Guaranà-containing products are usually recommended
for regular use: this is the main reason why our study was
concerned with the effects of guaranà regularly taken
according to the labeled dosages and instruction over sev-
eral days. The results of our study, which found no effect
of guaranà on psychological well-being, anxiety and mood,
are in line with previous studies reporting no activity of
guaranà [6,9]. We decided to assess the effects of guaranà
on psychological well-being since the possible increase of
“feelings of well-being” is among the most common claims
for guaranà-containing products in particular on the Inter-
net, where guaranà is one of the most popular herbal in-
gredients sought for the purpose of increasing alertness
and fitness [11], however to our knowledge no scientific
studies existed so far which addressed this issue. In our
study we used a guaranà extract commercially available
and standardized to 2.5% caffeine. Enrolled subjects took a
total of 1080 mg/day, according to labelled commercial in-
structions and corresponding to 27 mg caffeine per day.
Likely explanations for lack of effects and apparent dis-
crepancies with other studies (e.g. Haskell and co-workers
[4] who found positive effects on some ratings of the
Bond-Lader mood scales) include the possibility that the
selected tasks were insensitive to the levels of treatment
used, or the testing regimens were not adequate to ob-
serve the effects of guaranà. Indeed, caffeine is one of the
main chemicals in guaranà seeds, its content being usually
4-8% [1]. The half-life of caffeine however is about 5 h
(see e.g. [17]), therefore any acute effects are likely to dis-
appear in a short time, while the supposed long-term ben-
efits of frequent caffeine consumption (e.g. reduced risk of
type 2 diabetes and liver cancer) possibly require years of
more or less regular intake (see e.g. [18,19]): it cannot be
excluded that the same applies to the possible effects of
caffeine on mood, which so far never received thorough
investigation [12].
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significant effect of a 5-day treatment with a commercial
preparation of guaranà on psychological well-being, anx-
iety and mood in healthy subjects. A number of adverse
events are reported with the use of herbal food supple-
ments containing guaranà, including irritability, heart pal-
pitations, anxiety and other central nervous system events
[20], especially in children, adolescents, and young adults
with seizures, diabetes, cardiac abnormalities, or mood
and behavioral disorders or those who take certain medi-
cations [21]. Also in view of the weak evidence available
regarding the actual effectiveness of commercial products
containing guaranà, caution shoud be always used and ad-
vised to potential users. Considering the increasing popu-
larity of products containing guaranà – as well as a
number of other traditional herbs – and sold as dietary
supplements for health and fitness purposes, controlled
studies are strongly warranted to assess their benefits in
comparison to the labelled claims.
Methods
Subjects
We enrolled 27 volunteers (9 female and 18 male, age
(mean ± SD) 25.4 ± 6.4 years). Subjects taking part in the
study were acquaintances of the students attending the
Course in Motorial Sciences at the Faculty of Medicine, Uni-
versity of Insubria (Varese, I). All the subjects reported good
health, were not cigarette smokers and did not report use of
over-the-counter, medication (including hormonal contra-
ceptive methods) and/or illicit drugs in the previous three
months. Participants were told that the study aimed at the
evaluation of the effects of mood of a commerncial product
containing guaranà used according to the commercial advice
and that, to this end, they would have received during dis-
tinct 5-day periods in random sequence capsules containing
guaranà or corn starch. All the participants provided written
informed consent and the study was performed according
to ethical guidelines for research on humans.
Study products
We used a commercial guaranà extract kindly provided
by Anderson Research (Cassino, FR, Italy; http://www.
anderson-research.com). The extract contained caffeine
2.5% (w/w) and was prepared in 360 mg capsules.
According to labelled instructions, 3 capsules/day should
be taken, with no recommendations regarding duration
of use. Placebo capsules contained 360 mg of cornstarch.
Study design
The study was a prospective, randomized, single-blind,
placebo-controlled, crossover study evaluating the effects
on psychological well-being, anxiety and mood of the intake
for five consecutive days of a guaranà extract at 360 mg × 3
daily just after breakfast, according to labelled advice.Procedure
Each participant was required to attend a total of 4
evaluation sessions (pretreatment, treatment 1, washout,
treatment 2), which comprised completion of the psy-
chological well-being scales (PWB) [13], the self-rating
anxiety state scale (SAS) [16], and the Bond–Lader Vis-
ual Analogue Scales [22]. Testing took place during the
morning between 9:00am and 11:00am in a room of the
laboratories, and subjects were visually isolated from
each other during the whole session. The pretreatment
session (day 1) was identical to the others and was de-
vised to eliminate practice effects and to familiarize par-
ticipants with the evaluation procedures. Participants
were then randomized to guaranà or placebo and re-
ceived 15 capsules and the instructions about how to
take them each day (3 capsules/day immediately after
breakfast with half glass of water) for five consecutive
days (days 2–6). Then participants underwent the sec-
ond evaluation session (day 7, treatment 1) and then a
washout period of additional five days (days 8–12),
which was followed by an evaluation session (day 13,
washout) and by a second 5-day period of treatment
(days 14–18, crossover: placebo or guaranà according to
what they received in the first period). The day after the
end of the second treatment period (day 19) participants
underwent the final evaluation session (treatment 2).
Evaluation sessions following treatment periods always
included a standard interview about any possible adverse
events.
Subjects were blind to treatments. Random allocation to
guaranà or placebo was accomplished by use of a random
number calculator (QuickCalcs, GraphPad Software, La
Jolla California USA, www.graphpad.com). During the first
period of treatment 9 subjects received guaranà and 15 re-
ceived placebo, and were subsequently switched to pla-
cebo and guaranà, respectively, during the second period.
Before each period of treatment, each subject received 15
capsules (either guaranà or placebo, 3 per day for 5 con-
secutive days) and was asked to bring back any remaining
capsules on the day of the evaluation, to check for compli-
ance. Capsules were handed together with the brochure of
the commercial product containing guaranà, to expose
subjects to standard information provided when the prod-
uct is normally purchased.
During the study, subjects were asked to abstain from
alcoholic and caffeine-containing beverages, except for a
maximum of 4 cups of coffee (italian “espresso”) per
day, and to abstain also from coffee in the morning of
the weekly testing session. No other dietary restrictions
were imposed.
Psychological well-being (PWB) scales
The long form (84 questions) of the PWB scales devel-
oped by Carol D. Ryff [13,14] was used. The scales
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psychological well-being: autonomy, environmental mas-
tery, personal growth, positive relations with others, pur-
pose in life, and self-acceptance. Respondents rate
statements on a scale of 1 to 6, with 1 indicating strong
disagreement and 6 indicating strong agreement. Re-
sponses are totaled for each of the six categories (about
half of the responses are reverse scored). For each cat-
egory, a high score indicates that the respondent masters
that area in life, while a low score shows that the re-
spondent struggles to feel comfortable with that particu-
lar concept. PWB scales have been recently validated for
use in the italian population [15].
Self-rating anxiety scale (SAS)
The SAS [16] was used to quantify the level of anxiety.
The scale is a 20-item self-report assessment device in-
cluding measures of state and trait anxiety. Respondent
is asked to indicate how much each statement applies to
her or him. Each question is scored on a Likert-type
scale of 1–4 (based on the following replies: “a little of
the time,” “some of the time,” “good part of the time,”
and “most of the time”). Overall assessment is done by
total score, after reverse scoring some of the responses.
The total scores range from 20–80: 20–44 normal, 45–
59 mild to moderate anxiety, 60–74 marked to severe
anxiety, 75–80 extreme anxiety.
Bond–lader visual analogue scales (VAS)
The Bond–Lader VAS [22], consisting of sixteen 100-
mm visual analogue scales anchored by antonyms (e.g.
Alert–Drowsy, Lethargic–Energetic, etc.), were used to
assess subjective mood. The scales reflect three key
mood factors: “alert” (alert-drowsy, attentive-dreamy,
lethargic-energetic, muzzy-clearheaded, coordinated-clumsy,
mentally slow-quick witted, strong-feeble, interested-bored,
incompetent-proficient), “calm” (calm-excited, tense-relaxed)
and “content” (contented-discontented, troubled-tranquil,
happy-sad, antagonistic-friendly, withdrawn-sociable). Scores
for each item represent the number of mm from the nega-
tive antonym. Item scores were summed and averaged to
create total scores for each respective factor. Factor scores
had a potential range between 0 and 100, with 100
representing highly alert, calm or content. A pen-
and-paper version was used and participants were asked
to mark each line between the antonyms indicating how
they felt at the present time.
Data analysis
Data are presented as means ± standard deviation (SD)
with n indicating the number of observations. Statistical
significance of the differences between sessions were eval-
uated by means of One-Way ANOVA for repeated mea-
sures with Tukey’s correction for multiple comparisons.Statistical significance of the differences was also assessed
according to gender and to the median score obtained for
each scale after placebo, to test for any difference between
lower- and higher-scoring subjects.
Statistical analysis was performed using GraphPad
Prism version 6.00 for Mac (GraphPad Software). Sam-
ple size calculations could not be performed in advance,
since there is no general consensus about the smallest
average differences which would be scientifically import-
ant for each of the scales employed. The power of the
study to detect the least hypothetical difference between
the effects of guaranà and placebo was therefore deter-
mined for each test after completion of the study. Calcu-
lations were performed by use of GraphPad StatMate for
Windows (GraphPad Software).
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